| Summary: | The study objective is to analyze the effect of Prostatilen® AC on sperm DNA fragmentation during treatment of patients with chronic nonbacterial prostatitis and concomitant disorders of the reproductive function.Materials and methods. The study is based on the results of treatment of 25 men aged 24 to 45 years (mean age 35.3 ± 4.4 years) with a verified diagnosis of chronic nonbacterial prostatitis and complaints of early-stage missed miscarriage in a spouse/sexual partner. All patients received Prostatilen® AC daily in rectal suppositories formulation. The duration of treatment was 10 days with retreatment after 20 days. In all patients before treatment and 20 days after it, spermiogram parameters (5th ed., WHO, 2010) and sperm DNA fragmentation level using SCSA (sperm chromatin structure assay) by FACSCantoll with monoclonal antibodies (Roche, Germany) were determined, and all patients underwent the MAR (mixed antiglobulin reaction) test with normal value considered to be 10 % or less. The normal value of sperm DNA fragmentation was considered to be 15 % or less (low risk of fertility impairment). The analysis of the obtained data was carried out using the IBM SPSS Statistics program 22.Results. Before the treatment, pathologic level of sperm DNA fragmentation was observed in 6 (43 %) of 14 patients with normozoospermia and in 7 (63 %) of 11 patients with pathozoospermia (χ² = 1.06; p <0.3). Thus, there weren’t any significant difference between the rates of occurrence of increased sperm DNA fragmentation in patients with normo- and pathozoospermia. A correlation was found between the level of sperm DNA fragmentation and the results of MAR test before treatment (r = 0.8, p <0.05), which varied between 0 and 99 % (mean 16.48 ± 31.64 %). Meanwhile, increased sperm DNA fragmentation was observed in 7 (53 %) of 13 patients with pathological MAR test results, and in 2 (40 %) of 5 patients with normal MAR test results (χ² = 0.67; p <0.01). The level of sperm DNA fragmentation prior to treatment varied between 1 and 55 % (mean 18.99 ± 6.87 %), and after treatment it varied between 1 and 26 % (mean 9.76 ± 4.32 %). Increased level of sperm DNA fragmentation was observed in 13 (52 %) of 25 patients before treatment with Prostatilen® AC and only in 3 (12 %) patients after the treatment (χ² = 0.86; p < 0.001).Conclusion. Prostatilen® AC as treatment of chronic nonbacterial prostatitis promotes a decrease in the level of sperm DNA fragmentation.
|
|---|
